425, Summer St

Boston,

MA,

USA,

ZIP: 02210

Phone: +16174554188

Accelerate Novel Lipid Discovery, Optimized Formulation and Tightened CQAs for Process Development to Achieve Scalability and Regulatory Compliance for Improved Product Quality and Widened Therapeutic Windows
Building on the success of our 2022 summit, we are bringing the inaugural LNP Formulation and Process Development Summit back and better than ever in 2023.

In April 2023, the 2nd Annual LNP Formulation and Process Development meeting is returning to Boston to welcome 350+ LNP Biology, Chemistry, Formulation and Process Development, Tech Ops and Manufacturing experts for sharing, learning and networking to turbocharge next generation of LNP development.

With expanded content, the 3-tracks summit will now offer the most comprehensive content, equipping you with end-to-end LNP development journey to exploit this lucrative non-viral delivery vehicle for various payloads to your destined cells and organs.

Join the ever-growing audience of LNP experts seeking to overcome the challenges of developing LNPs for a variety of applications and payloads, from discovery, formulation and process development, lipid supply and scale up manufacturing departments. 

Hear from likes of Omega Therapeutics, AstraZeneca, Pfizer, Beam Therapeutics, Alnylam Pharmaceuticals and more.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

URLs:
Tickets: https://go.evvnt.com/1449061-0?pid=1052
Brochure: https://go.evvnt.com/1449061-3?pid=1052

Prices:
Drug Developer Pricing - Full Access Pass (Conference + Focus Day): USD 4997.00,
Drug Developer Pricing - Conference only (2 day pass): USD 3499.00,
Academic Pricing - Full Access Pass (Conference + Focus Day): USD 4197.00,
Academic Pricing - Conference only (2 day pass): USD 2899.00,
Service Provider Pricing - Full Access Pass (Conference + Focus Day): USD 5597.00,
Service Provider Pricing - Conference only (2 day pass): USD 4099.00

Speakers: Yuchen Fan, Principal Scientist, Genentech Inc, Manuel Sanchez-Felix, Senior Fellow - Novel Delivery Technologies, Novartis AG, Neha Kaushal, Principal Scientist, Sanofi mRNA Center of Excellence, Dan Peer, Professor and Vice President for Research and Development, Tel-Aviv University, Zohreh Amoozgar, Principal Scientist and Head of Lab, Sanofi, Sune Andersen, Principal Scientist - Spray Drying, Janssen Research and Development, LLC, Siddharth Bhoraskar, Scientist II, Beam Therapeutics, Jayant Arora, Principal Scientist - Product and Process Development Group Leader, Johnson and Johnson, Maria Monica, Castellanos Associate Director, GSK, Jeffrey Atkinson, Executive Director, Process Development and Analytical Sciences, Omega Therapeutics, Lubomir Nechev, Sr. Vice President, CMC Development, Alnylam Pharmaceuticals, Ping Wee, Lead Scientist - Formulations and Process Control, Entos Pharmaceuticals, David Karakas, Senior Director - Procurement and Strategic Sourcing, Tessera Therapeutics, Maximiliano Cacicedo, Postdoc, Mainz University Medical Center, Michael Munson, Senior Research Scientist, AstraZeneca, Paul Peng, Director - Oligonucleotide Technical Development, Biogen, Rahul Keswani, Associate Director - Non-Viral Gene Therapy, Arbor Biotechnologies, David Peritt, Founder and CSO, Lupagen, Torben Moos, Professor, Aalborg University, Philip Rye, Chief Scientific Officer, AlgiPharma AS, Julie Shi, Associate Director - Non-Viral Gene Delivery, Bristol-Myers Squibb Co., Thomas Cleveland, Physicist, National Institute of Standards and Technology - NIST, Zhengrong Cui, Professor Molecular Pharmaceutics and Drug Delivery Alfred and Dorothy Mannino Fellow in Pharmacy, University of Texas, Mohit Gupta, Senior Scientist, Tessera Therapeutics, Patrick J. (P.J) Brooks, Acting Director, Division of Rare Diseases Research Innovation, NCATS, Venkat Krishnamurthy, Senior Vice President, Korro Bio, Amit Singh, Head of Non Viral, Takeda, Sean Lu, Director of Chemistry, Sirnaomics, Russell Johnson, Vice President Formulation Research, RVAC Medicines, Yongchao Su, Principal Scientist, Merck and Co, Russell Johnson, Vice President - Formulation Research, RVAC Medicines, Sakya Mohapatra, Director - Formulation Development, ReCode Therapeutics, Inc, Luis Santos, Director - Non-Viral Delivery, mRNA, Lipid Nanoparticles and Product Development, Prime Medicine, John Androsavich, Global Head, RNA Medicine Lead, Pfizer, Weiyu Zhao, Senior Scientist, Strand Therapeutics Inc., Yizhou Dong, Associate and Assistant Professor, Ohio State University, Cory Sago, Former Senior Director and Head of Lipid Nanoparticle Discovery, Beam Therapeutics, Kalina Paunovska, Co-founder, Nava Therapeutics, Nawel Khalef, Associate Professor, University of Grenoble Alpes, Charles Chen, Senior Scientist, AstraZeneca, Ashiqul Haque, Senior Researcher, Ziphius Vaccines NV, Liping Zhou, Senior Director - Advanced Drug Delivery, AstraZeneca, Elizabeth Thoryk, Associate Principal Scientist, Merck and Co, Daniel Shores, Partner,  Rothwell, Figg, Ernst and Manbeck, Marianna Yanez, Arteta Associate Director, AstraZeneca, Nii Odoi Oddoye, Senior Manager, Pfizer, Diane Burgess, Distinguished Professor, Distinguished Chair in Pharmaceutical Technology, University of Connecticut, Dennis Lee, Senior Program Officer, Bill and Melinda Gates Foundation, Anni Chang, Senior Scientist II, US Pharmacopeia, Daniel Anderson, Professor, MIT, Ramsey Majzoub, Senior Principal Scientist, Intellia Therapeutics, Viktor Lemgart, Research Fellow, Tidal Therapeutics, Priya Karmali, Vice President, Technology Innovation and Development, Arcturus Therapeutics, Daryl Drummond, Chief Scientific Officer, Akagera Medicines, Karine BROUDIC, Senior Toxicologist, Sanofi Research and Development, Mandy Janssen, Scientific Group Leader, NanoImaging Services, Tao Niu, AD, Vertex Pharmaceuticals